Biomarkers in Neurodegenerative Diseases (Q39413097)

11 September 2017

1 reference

title

Biomarkers in Neurodegenerative Diseases (English)

1 reference

11 September 2017

0 references

1 reference

Andreas Jeromin

1

1 reference

PubMed ID

28674995

11 September 2017

Robert Bowser

series ordinal

2

1 reference

11 September 2017

1 January 2017

1 reference

11 September 2017

Advances in neurobiology

1 reference

11 September 2017

15

1 reference

11 September 2017

491-528

1 reference

Rodent models of amyotrophic lateral sclerosis.

11 September 2017

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Biomarkers and surrogate endpoints in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Molecular mechanisms of long ncRNAs in neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

The Role of Long Noncoding RNAs in Neurodegenerative Diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Extracellular RNAs: development as biomarkers of human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Amyotrophic lateral sclerosis: Is the spinal fluid pathway involved in seeding and spread?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Post-lumbar puncture headache is reduced with use of atraumatic needles in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

The human plasma proteome: history, character, and diagnostic prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Exosomes: vesicular carriers for intercellular communication in neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Locus-specific mutation databases for neurodegenerative brain diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Candidate gene for the chromosome 1 familial Alzheimer's disease locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Genetics of dementia: update and guidelines for the clinician

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Clinical genetics of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Review: The genetics of Alzheimer's disease; putting flesh on the bones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Cerebrospinal fluid protein biomarkers for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-β in cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Biomarkers of Alzheimer disease in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

The resolution of neuroinflammation in neurodegeneration: leukocyte recruitment via the choroid plexus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Anti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer's Disease and Cerebral Amyloid Angiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Autoantibodies to amyloid-beta and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Biological marker candidates of Alzheimer's disease in blood, plasma, and serum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Amyloid-beta immunotherapy for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Antibody drugs for Alzheimer's show glimmers of promise.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Induction of autoantibodies to glutamate in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Differential neuroimmune markers to the onset of Alzheimer's disease neurodegeneration and dementia: autoantibodies to Abeta((25-35)) oligomers, S100b and neurotransmitters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Autoantibodies Toward the Angiotensin 2 Type 1 Receptor: A Novel Autoantibody in Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Angiotensin II modulates BBB permeability via activation of the AT(1) receptor in brain endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Roles of Brain Angiotensin II in Cognitive Function and Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Soluble multimeric Alzheimer beta(1-40) pre-amyloid complexes in dilute solution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Phases of A beta-deposition in the human brain and its relevance for the development of AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

PET imaging of amyloid deposition in patients with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

In vitro characterization of Pittsburgh compound-B binding to Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Antemortem amyloid imaging and β-amyloid pathology in a case with dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Positron emission tomography radioligands for in vivo imaging of Aβ plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Imaging β-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Technical Considerations in Brain Amyloid PET Imaging with 18F-Florbetapir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Use of Florbetapir-PET for Imaging β-Amyloid Pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Early detection of Alzheimer's disease using PiB and FDG PET

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Visualization of regional tau deposits using (3)H-THK5117 in Alzheimer brain tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

[(18)F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

PET Quantification of Tau Pathology in Human Brain with 11C-PBB3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Tau positron emission tomographic imaging in aging and early Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

PET Imaging of Tau Deposition in the Aging Human Brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Comparison of New Tau PET-Tracer Candidates With [18F]T808 and [18F]T807

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Three-dimensional surface mapping of hippocampal atrophy progression from MCI to AD and over normal aging as assessed using voxel-based morphometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Alterations in regional brain volume and individual MRI-guided perfusion in normal control, stable mild cognitive impairment, and MCI-AD converter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

In vivo mapping of amyloid toxicity in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Epidemiology of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Systematic review of incidence studies of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Parkinson's disease: clinical features and diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

The NINDS Parkinson's disease biomarkers program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Genetics of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Identification of TMEM230 mutations in familial Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

MicroRNAs in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Estimation of further disease progression of Parkinson's disease by dopamin transporter scan vs clinical rating

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

FDG PET in the differential diagnosis of parkinsonian disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

A review of the use of magnetic resonance imaging in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Longitudinal evaluation of cerebral morphological changes in Parkinson's disease with and without dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Five-year follow-up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Clinical and imaging markers in premotor LRRK2 G2019S mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

CSF biomarkers and clinical progression of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Plasma alpha-synuclein is decreased in subjects with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

α-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-naïve patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Plasma urate and risk of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Serum urate as a predictor of clinical and radiographic progression in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Striatal dopamine transporter binding correlates with serum BDNF levels in patients with striatal dopaminergic neurodegeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug-naïve Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Increased serum insulin-like growth factor 1 in early idiopathic Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

State of play in amyotrophic lateral sclerosis genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Astrocytes from familial and sporadic ALS patients are toxic to motor neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Protein biomarkers for amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Biomarkers in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

pNfH is a promising biomarker for ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Modeling ALS with iPSCs reveals that mutant SOD1 misregulates neurofilament balance in motor neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Elevated CSF TDP-43 levels in amyotrophic lateral sclerosis: Specificity, sensitivity, and a possible prognostic value

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

TDP-43 plasma levels are higher in amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Quantitative analysis and clinico-pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Blood biomarkers for amyotrophic lateral sclerosis: myth or reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Plasma biomarkers associated with ALS and their relationship to iron homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

CSF glial markers correlate with survival in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Metabolomic analysis of serum by (1) H NMR spectroscopy in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Uric acid levels predict survival in men with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

T helper-17 activation dominates the immunologic milieu of both amyotrophic lateral sclerosis and progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

18F-FDG-PET correlates of cognitive impairment in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Grey matter correlates of clinical variables in amyotrophic lateral sclerosis (ALS): a neuroimaging study of ALS motor phenotype heterogeneity and cortical focality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Focal thinning of the motor cortex mirrors clinical features of amyotrophic lateral sclerosis and their phenotypes: a neuroimaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Structural MRI reveals cortical thinning in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Cortical thickness in ALS: towards a marker for upper motor neuron involvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Utility of axial and radial diffusivity from diffusion tensor MRI as markers of neurodegeneration in amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Impaired structural motor connectome in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Structural brain network imaging shows expanding disconnection of the motor system in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Multimodal MRI as a diagnostic biomarker for amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Electrical impedance myography as a biomarker for ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Electrical impedance myography for monitoring motor neuron loss in the SOD1 G93A amyotrophic lateral sclerosis rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Electrical impedance myography as a biomarker to assess ALS progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

The relationship between Bayesian motor unit number estimation and histological measurements of motor neurons in wild-type and SOD1(G93A) mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Motor unit number estimation in evaluating disease progression in patients with amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Multipoint incremental motor unit number estimation as an outcome measure in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Motor unit number estimate-based rates of progression of ALS predict patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Mutant copper-zinc superoxide dismutase (SOD1) induces protein secretion pathway alterations and exosome release in astrocytes: implications for disease spreading and motor neuron pathology in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Isolation of exosomes for subsequent mRNA, MicroRNA, and protein profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Axonal damage markers in cerebrospinal fluid are increased in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Increased neurofilament light chain blood levels in neurodegenerative neurological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

(123I)FP-CIT SPECT in suspected dementia with Lewy bodies: a longitudinal case study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Three-dimensional Patterns of Hippocampal Atrophy in Mild Cognitive Impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Volumetric cortical loss in sporadic and familial amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Hippocampal atrophy and EEG markers in subjects with mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Serum uric acid levels and the risk of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Metabolomics in Cerebrospinal Fluid of Patients with Amyotrophic Lateral Sclerosis: An Untargeted Approach via High-Resolution Mass Spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Grey matter volume changes over the whole brain in amyotrophic lateral sclerosis: A voxel-wise meta-analysis of voxel based morphometry studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

Distinct patterns of cortical atrophy in ALS patients with or without dementia: An MRI VBM study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-57193-5_20

10.1007/978-3-319-57193-5_20

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference

PubMed ID

28674995